Primary Osteoporosis

  • H. Morii
  • T. Miki
  • M. Ito
  • Y. Uchida
  • Y. Takaishi
  • K. Nakatsuka
  • H. Tahara

Abstract

Osteoporosis is defined as a condition characterised by low bone mass, microarchitectural deterioration of bone tissue, leading to enhanced bone fragility and a consequent increase in fracture risk [1]. Since the first consensus development conference in Hong Kong in 1993 there have been no changes of the definition until 2001.

Keywords

Depression Cortisol Testosterone Glucocorticoid Progesterone 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Consensus Development Conference on Osteoporosis. Hong Kong, April 1–2, 1993. Am J Med. 1993;95(5A):1S–78S.Google Scholar
  2. 2.
    Khosla S, Riggs BL, Melton III LJ. Clinical spectrum. In: Riggs BL, Melton III LJ, editors. Osteoporosis: Etiology, diagnosis, and management 2nd ed. Philadelphia: Lippincott-Raven, 1995.Google Scholar
  3. 3.
    Martin BR. Aging and changes in cortical mass and structure. In: Orwoll ES, editor. Osteoporosis in Men. San Diego: Academic Press, 1999;Ch 7. Google Scholar
  4. 4.
    Genant HK, Cooper C, Poor G, Reid I, Ehrlich G, Kanis J et al. Interim report and recommendations of the World Health Organization Task Force for Osteoporosis. Osteoporosis Int 1999;10(4):259–64.CrossRefGoogle Scholar
  5. 5.
    WHO Study Group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Geneva: World Health Organization, 1994.Google Scholar
  6. 6.
    Lau EMC. The epidemiology of osteoporosis in Asia. In: Lau EDC, editor. Osteoporosis in Asia. Singapore: World Scientific, 1997.CrossRefGoogle Scholar
  7. 7.
    Yamamoto I. Estimation of osteoporosis population in Japan. Osteoporosis Jpn 1999;9:1183–64.Google Scholar
  8. 8.
    Ling XU, Cummings SR, Mingwel Q, Xihe Z, Xioashu C, Nevitt M etal. Vertebral fractures in Beijing, China: The Beijing Osteoporosis Project. J Bone Miner Res 2000;15:2019–25.PubMedCrossRefGoogle Scholar
  9. 9.
    Fujiwara S. Ross PD. Epidemiological studies of osteoporosis in Japan. In: Lau EMC, editor. Osteoporosis in Asia. Singapore: World Scientific, 1997;21–29.CrossRefGoogle Scholar
  10. 10.
    Nordin BEC. Nutritional considerations. In: Nordin BEC, editor. Calcium, phosphate and magnesium metabolism. Edinburgh: Churchill Livingsone, 1976; 1–35.Google Scholar
  11. 11.
    Garraway WM, Stauffer RN, Kurland LT, O’Fallon WM. Limb fractures in a defined community. 1. Frequency and distribution. Mayo Clinic Proc 1979;54:701–7. Google Scholar
  12. 12.
    Orimo H et al. Survey of hip fracture in Japan. Japan Med Archiv 1999;3916:46–49.Google Scholar
  13. 13.
    Schwartz AV, Kelsey JL, Maggi S, Tuttleman M, Ho SC, Jonsson PV etal. International variation in the incidence of hip fractures: cross-national project on osteoporosis for the World Health Organization Program for Research on Aging. Osteoporos Int 1999;9:242–53.PubMedCrossRefGoogle Scholar
  14. 14.
    Johnell O, Gullberg B, Kanis JA, Allander E, Elffors L, Dequeker J etal. Risk factors for hip fracture in European women: the MEDOS Study. Mediterranean Osteoporosis Study. J Bone Miner Res 1995;10:1802–15. Google Scholar
  15. 15.
    Suzuki T, Yoshida H, Hashimoto T, Yoshimura N, Fujiwara S, Fukunaga M et al. Case-control study of risk factors for hip fractures in the Japanese elderly by a Mediterranean Osteoporosis Study (MEDOS) questionnaire. Bone 1997;21:461–7.PubMedCrossRefGoogle Scholar
  16. 16.
    Morii H, Shioi A, Inaba M, Goto H, Kawagishi T, Nakatsuka K etal. Significance of albumin in the pathogenesis of osteoporosis: Bone changes in genetically analbuminaemic rats and rats fed a low albumin diet. Osteoporos Int 1997;7 Suppl 3:S30–35.PubMedCrossRefGoogle Scholar
  17. 17.
    Schurch MA, Rizzoli R, Vadas L, Slosman DO, Bonjour JP. Protein supplements in the elderly with a recent fracture increase serum IGF-1, decrease urinary deoxypyridinoline, and prevent proximal femur bone loss. J Bone Miner Res 1996; 11 (suppl 1) S139. Google Scholar
  18. 18.
    Nordin BEC. The calcium controversy. Osteoporos Int 1997;7(suppl 3):S 17–23. Google Scholar
  19. 19.
    Reid IR, Ames RW, Evans MC, Gamble GD, Sharpe SJ. Long-term effects of calcium supplementation on bone loss and fractures in postmenopausal women: a randomized controlled trial. Am J Med 1995;98:331–3.PubMedCrossRefGoogle Scholar
  20. 20.
    Ott SM. Calcium and vitamin D in the pathogenesis of osteoporosis. In: Marcus R, editor. Osteoporosis. Oxford, UK: Blackwell Scientific Publications, 1994;237–92.Google Scholar
  21. 21.
    Caniggia A, Lore F, di Cairano G, Nuti R. Main endocrine modulators of vitamin D hydroxylases in human pathophysiology. J Steroid Biochem 1987;27(4–6):815–24.PubMedGoogle Scholar
  22. 22.
    McKenna MJ, Freaney R. Secondary hyperparathyroidism in the elderly: Means to defining hypovitaminosis D. Osteoporos Int 1998;8(Suppl 2):S3–6.PubMedCrossRefGoogle Scholar
  23. 23.
    Albrigth F, Reifenstein J. The parathyroid glands and metabolic bone disease. Baltimore: Williams & Wikins, 1948.Google Scholar
  24. 24.
    DeLuca HF. 1,25-dihydroxyvitamin D3 in the pathogenesis and treatment of osteoporosis. Osteoporos Int 1997;7(Suppl 3):S24–9.PubMedCrossRefGoogle Scholar
  25. 25.
    National Osteoporosis Foundation. Osteoporosis: Review of the evidence for prevention, diagnosis, and treatment and cost-effectiveness analysis. Osteoporos Int 1998;8(Suppl 4).Google Scholar
  26. 26.
    Chapuy MC, Preziosi P, Maamer M, Arnaud S, Galan P, Hereberg S etal. Prevalence of vitamin D insufficiency in an adult normal population. Osteoporos Int 1997;7:439–43.PubMedCrossRefGoogle Scholar
  27. 27.
    Chapuy MC, Arlot ME, Duboeuf F, Brun J, Crouzet B, Arnaud S etal. Vitamin D3 and calcium to prevent hip fractures in elderly women. N Engl J Med 1992;327:1637–42.PubMedCrossRefGoogle Scholar
  28. 28.
    Scharla SH. Prevalence of subclinical vitamin D deficiency in different European countries. Osteoporos Int 1998;8(Suppl 2):S7–12.PubMedCrossRefGoogle Scholar
  29. 29.
    Meunier P. Osteoporosis: Diagnosis and management. London: Martin Dunitz, 1998.Google Scholar
  30. 30.
    Ringe JD. Vitamin D deficiency and osteopathies. Osteoporos Int 1998;8(Suppl 2):S35–9. PubMedCrossRefGoogle Scholar
  31. 31.
    Parfitt AM. Osteomalacia and related disorders. In: Avioli LV, Krane SM editors. Metabolic Bone Disease and Clinically Related Disorders, IIIrd ed. Academic Press, San Diego 1998;327–86.CrossRefGoogle Scholar
  32. 32.
    Harris S, Soteriadew E, Coolidge JAS, Mudgal S, Dawson-Hughes B. Vitamin D insufficiency and hyperparathyroidism in low income, multiracial, elderly population. J Clin Endocrinol Metab 2000;85: 4125–30.PubMedCrossRefGoogle Scholar
  33. 33.
    Melin AL, Wilske J, Ringertz, Saaf M. Vitamin D status, parathyroid function and femoral bone density in an elderly Swedish population living at home. Aging (Milano) 1999;11:200–7. Google Scholar
  34. 34.
    Sahota O, Masud T, San P, Hosking DJ. Vitamin D insufficiency increases bone turnover markers and enhances bone loss at the hip in patients with established vertebral osteoporosis. Clin Endocrinol (Oxf) 1999;51:217–21.CrossRefGoogle Scholar
  35. 35.
    Peacock M, Liu G, Carey M, McClintock R, Ambrosius W, Hui S etal. Effect of calcium or 25 OH vitamin D3 dietary supp. Clin Endocrinol METAB 2000;85:3009–10.CrossRefGoogle Scholar
  36. 36.
    Nakamura T. The importance of genetic and nutritional factors in responses to vitamin D and its analogs in osteoporotic patients. Calcif Tissue Int 1997;60:119–23.PubMedCrossRefGoogle Scholar
  37. 37.
    Tilyard M, Spears GF, Thomson J, Davey S. Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med 1992;326:357–62.PubMedCrossRefGoogle Scholar
  38. 38.
    Tanizawa T, Imura K, Ishii Y, Nishida S, Takano Y, Mashiba T et al. Treatment with active vitamin D metabolites and concurrent treatments in the prevention of hip fractures: A retrospective study. Osteoporos Int 1999;9:163–70.PubMedCrossRefGoogle Scholar
  39. 39.
    Masaki T, Shiraishi A, Higashi S, Uchida Y, Saito M, Ogata E etal. Superiority of alphacalcidol over plain vitamin D: Failure to increase bone strength at cortical site by the treatment with plain vitamin D but no alphacalcidol might be related to the enhanced porosity. J Bone Miner Res 2000;15(Suppl 1)M449;S563. Google Scholar
  40. 40.
    Shiraishi A, Higashi S, Masaki T, Uchida Y, Saito M, Ito M etal. Improvement of bone strength by alphacalcidol treatment: Relationship to trabecular microarchitecture and antiresorptive activity. J Bone Miner Res 2000;15(Suppl 1)SA449;S315. Google Scholar
  41. 41.
    Matsumoto T, Miki T, Sugimoto T, Teshima R, Kato Y, Okamoto S etal. A new active vitamin D analog, ED-71, increases bone mass with preferential effects on bone in osteoporotic patients. J Bone Miner Res 2001;(Suppl 1) to be presented in October, 2001.Google Scholar
  42. 42.
    Cooper C, Melton III LJ. Magnitude and impact of osteoporosis and fractures. In: Marcus R, Feldman D, Kelsey J, editors. Osteoporosis. San Diego: Academic Press, 1996.Google Scholar
  43. 43.
    Ensrud KE, Thompson DE, Cauley JA, Nevitt MC, Kado DM, Hochberg MC etal. Prevalent vertebral deformities predict mortality and hospitalization in older women with low bone mass, Fracture Intervention Trial Research Group. J Am Geriar Soc 2000;48:241–9.Google Scholar
  44. 44.
    Shah MR, Aharonoff GB, Wolinsky P, Zuckerman JD, Koval KJ. Outcome after hip fracture in individuals ninety years of age and older. J Orthop Trauma 2001;15:34–9.PubMedCrossRefGoogle Scholar
  45. 45.
    Huddleston JM, Whitford KJ. Medical care of elderly patients with hip fractures. Mayo Clin Proc 2001;76:295–8 (referred to Medline). PubMedCrossRefGoogle Scholar
  46. 46.
    Doherty DA, Sanders KM, Kotowicz MA, Prince RL. Lifetime and five-year age-specific risks of first and subsequent osteoporotic fractures in postmenopausal women. Osteoporos Int 2001;12:16–23.PubMedCrossRefGoogle Scholar
  47. 47.
    Davison JN, Caider SJ, Anderson GH, Ward G, Japper C, Harper WM etal. Treatment for displaced intracapsular fracture of the proximal femur. A prospective, randomized trial in patients aged 65 to 79 years. J Bone Joint Surg Br 2001;83:206–12 (referred to Medline). PubMedCrossRefGoogle Scholar
  48. 48.
    Browner WS, Lui L-Y, Cummings SR. Association of serum osteoprotegerin levels with diabetes, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab 2001;86:631–7.PubMedCrossRefGoogle Scholar
  49. 49.
    Kado DM, Browner WS, Blackwell T, Gore R, Cummings SR. Role of bone loss is associated with mortality in older women: A prospective study. J Bone Miner Res 2000;15:1974–80.PubMedCrossRefGoogle Scholar
  50. 50.
    Jorgensen L, Engstad T, Jacobsen BK. Bone mineral density in acute stroke patients: Low bone mineral density may predict first stroke in women. Stroke 2001;32:47–51.PubMedCrossRefGoogle Scholar
  51. 51.
    Bulpitt C, Fletcher A, Beckett N, Coope J, Gil-Extremera B, Forette F etal. Hypertension in the very elderly trial (HYVET) protocol for the main trial. Drugs Aging 2001;18:151–64.PubMedCrossRefGoogle Scholar
  52. 52.
    Inaba K, Kirkpatrick AW, Finkelstein J, Murphy J, Brenneman FD, Boulanger BR etal. Blunt abdominal aortic trauma in association with thoracolumbar spine fractures. Injury 2001;32:201–7.PubMedCrossRefGoogle Scholar
  53. 53.
    Fujita T, Orimo H, Inoue T, Kaneda K, Sakurai M, Morita R et al. Double-blind, multicenter comparative study with alphacalcidol of etidronate disodium (EHDP) in involutional osteoporosis. Clin Eval 1993;21:261–302.Google Scholar
  54. 54.
    Scarpelli PT, Livi R, Caselli GM, Di Maria L, Teghini L, Montemurro V et al. Accelerated (malignant) hypertension: a study of 121 cases between 1974 and 1996. J Nephrol 1997;10:207–15.PubMedGoogle Scholar
  55. 55.
    Scarpelli PT, Livi R, Caselli GM, Chiari G, Gallo M, Teghini L etal. Hypertensive vascular crisis secondary to chronic total renal artery occlusion. J Nephrol 1998;11:325–9.PubMedGoogle Scholar
  56. 56.
    Weisfeldt M. Aging, changes in the cardiovascular system, and response to stress. Am J Hypertens 1998;11:41S.PubMedCrossRefGoogle Scholar
  57. 57.
    Shioi A. Vascular calcification. This monograph.Google Scholar
  58. 58.
    Demer LL. A skeleton in the atherosclerotic closet. Circulation 1995;92:2029–31.PubMedGoogle Scholar
  59. 59.
    Kiel DP, Hannan MT, Cupples LA, Wilson PWF, Levy W, Clouse ME etal. Low bone mineral density (BMD) is associated with coronary artery calcification. J Bone Miner Res 2000;15(Suppl 1):S160,1087. Google Scholar
  60. 60.
    Kampman E, Stattery ML, Caan B, Potter JD. Calcium, vitamin D, sunshine exposure, dairy products and colon cancer risk (United States). Cancer Causes Control 2000;11:459–66.PubMedCrossRefGoogle Scholar
  61. 61.
    Garland CF, Garland FC, Gorham ED. Calcium and vitamin D. Their potential roles in colon and breast cancer prevention. Ann NY Acad Sci 1999;889:107–19. Google Scholar
  62. 62.
    Dalberg J, Jacobsen O, Nielsen NH, Steig BA, Storm HH. Colorectal cancer in the Faroe Islands - a setting for the study of the role of diet. J Epidemiol Biostat 1999;4:31–6.PubMedGoogle Scholar
  63. 63.
    Otoshi T, Iwata H, Kitano M, Nishizaawa Y, Morii H, Yano Y etal. Inhibition of intestinal tumor development in rat multi-organ carcinogenesis and aberrant crypt foci in rat colon carcinogenesis by 22 oxacalcitriol, a synthetic analogue of la, 25-dihydroxyvitamin D3. Carcinogenesis 1995;16:2091–7.PubMedCrossRefGoogle Scholar
  64. 64.
    Taniyama T, Wanibuchi H, Salim EI, Yano Y, Otani S, Nishizawa Y etal. Chemopreventive effect of 24R,25-dihydroxyvitamin D3 in N, N’-dimethyohydrazine-induced rat colon carcinogenesis. Carcinogenesis 2000;21:173–8.PubMedCrossRefGoogle Scholar
  65. 65.
    Sato K, Tominaga Y, Ichikawa F, Uchida K, Takezawa J, Tsuchiya T et al. In vitro suppression of parathyroid hormone secretion by 22-oxa-calcitriol in human parathyroid hyperplasia due to uraemia. Nephrology 1998;4:177–82.CrossRefGoogle Scholar
  66. 66.
    Buist DS, LaCroix AZ, Barlow WE, White E, Weiss NS. Bone mineral density and breast cancer risk in postmenopausal women. J Clin Epidemiol 2001;54:417–22.PubMedCrossRefGoogle Scholar
  67. 67.
    Barger-Lux MJ, Heaney RP. The role of calcium intake in preventing bone fragility, hypertension, and certain cancers. J Nutr 1994;124:1406S–11S.PubMedGoogle Scholar
  68. 68.
    Abe J, Nakano T, Nishii Y, Matsumoto T, Ogata E, Ikeda K. A novel vitamin D analog, 22-oxa- 1α,25dihy- droxyvitamin D3 inhibits the growth of human breast cancer in vitro and in vivo without causing hypercalcemia. Endocrinology 1991;129:832–7.PubMedCrossRefGoogle Scholar
  69. 69.
    Bretherton-Watt D, Given-Wilson R, Mansi JL, Thomas V, Carter N, Colston KW. Vitamin D receptor gene polymorphisms are associated with breast cancer risk in a UK Caucasian population. Br J Cancer 2001;85:171–5.PubMedCrossRefGoogle Scholar
  70. 70.
    Jordan S. Progress in the prevention of breast cancer: incept to reality. J Steroid Biochem Mol Biol 2000;74:269–77.PubMedCrossRefGoogle Scholar
  71. 71.
    Tezal M, Wactawski-Wende J, Grossi SG, Ho AW, Dunford R, Genco RJ. The relationship between bone mineral density and periodontitis in postmenopausal women. J Periodontol 2000;71:1492–8.PubMedCrossRefGoogle Scholar
  72. 72.
    Payne JB, Reinhardt RA, Nummikoski PV, Patil KD. Longitudinal alveolar bone loss in postmenopausal osteoporotic/osteopenic women. Osteoporos Int 1999;10:34–40. PubMedCrossRefGoogle Scholar
  73. 73.
    Fleisch H. Bisphosphonates in bone disease. 4th ed. San Diego: Academic Press, 2000.Google Scholar
  74. 74.
    Jeffcoat MK, Reddy MS. Alveolar bone loss and osteoporosis: evidence for a common mode of therapy using the bisphosphonate alendronate. In: Davidovitch Z, Norton LA, editors. Biological mechanisms of tooth movement and cranofacial adaptation. Proc Second Int Conf at Tara Ferncroft Conference Resort, Danvers, MA, 1995;Oct 19–22:365. Google Scholar
  75. 75.
    Takaishi Y, Miki T, Nishizawa Y, Morii H. Clinical effect of etidronate on alveolar pyorrhea associated with chronic marginal periodontitis. J Int Med Res 2001;29:355–65.PubMedGoogle Scholar
  76. 76.
    Horrobin DF, Bennett CN. Depression and bipolar disorder: relationships to impaired fatty acid and phospholipid metabolism and to diabetes, cardiovascular disease, immunological abnormalities, cancer, ageing and osteoporosis. Possible candidate genes. Prostaglandins Leukot Essent Fatty Acids 1999;60:217–34. CrossRefGoogle Scholar
  77. 77.
    Coelho R, Silva C, Maia A, Prata J, Barros H. Bone mineral density and depression: a community study in women. J Psychosom Res 1999;46:29–35.PubMedCrossRefGoogle Scholar
  78. 78.
    Lips P, Cooper C, Agnusdei D, Caulin F, Egger P, Jonell O etal. Quality of life in patients with vertebral fractures: validation of the Quality of Life Questionnaire of the European Foundation for Osteoporosis (QUALEFFO) Working Party for Quality of Life of the European Foundation for Osteoporosis. Osteoporos Int 1999;10:150–60.PubMedCrossRefGoogle Scholar
  79. 79.
    Whooley MA, Kip KE, Cauley JA, Ensurud KE, Nevitt MC, Browner WS. Depression, falls, and risk of fracture in older women. Study of Osteoporotic Fractures Research Group. Arch Intern Med 1999;159:484–90. Google Scholar
  80. 80.
    Azuma M, Shirota K, Yasumori Y, Tabata K, Maeda Y, Yoshimura Y etal. Quality of life form mental state in patients with osteoporosis. Osteoporosis Jpn 2000;8:269–71 (in Japanese). Google Scholar

Copyright information

© Springer-Verlag London Limited 2002

Authors and Affiliations

  • H. Morii
  • T. Miki
  • M. Ito
  • Y. Uchida
  • Y. Takaishi
  • K. Nakatsuka
  • H. Tahara

There are no affiliations available

Personalised recommendations